Navigation Links
ResearchDx and Menarini Silicon Biosystems Launch DEPArray HER2 for Breast and GEA Cancers
Date:10/5/2017

ResearchDx, the leading biopharma companion diagnostics provider and Menarini Silicon Biosystems, worldwide manufacturer of image-based cell sorting products and services, jointly announce the launch of DEPArray HER2. The fluorescence in situ hybridization (FISH)-based assay has been validated as a clinical research laboratory developed test (LDT) and is performed by PacificDx, a CAP/CLIA certified and wholly owned subsidiary laboratory of ResearchDx.

Close to 300,000 breast and gastroesophageal adenocarcinoma (GEA) tumors are diagnosed each year in the United States. An estimated 20% of those tumors harbor HER2 gene amplifications. Accurate assessment of HER2 status in breast and GEA cancers is critical for identifying patients predicted to respond to anti-HER2 targeted therapies. Traditional tissue-based assessment of HER2 gene status can be problematic due the mixture of tumor and stromal (normal) tissue in a standard biopsy sample. Compounding the problem of tissue heterogeneity is the known intra-tumor genetic heterogeneity of many breast and GEA cancers such that only a small percentage of the tumor contains HER2 gene amplification.

The DEPArray HER2 test leverages cell isolation capabilities of DEPArray™ NxT technology allowing isolation of pure tumor cell populations from heterogeneous tumor/normal tissue samples. The HER2 test is performed on pure tumor populations isolated from stained cell suspensions digitally sorted using the DEPArray NxT, thus eliminating tissue heterogeneity and allowing true genetic heterogeneity to be revealed more accurately.

“We are the first clinical laboratory to offer HER2 gene testing on pure cell populations isolated from tumor tissue by DEPArray NxT technology,” said Shelly Gunn MD, PhD. ResearchDx’s Chief Medical Officer and Medical Director of the PacificDx clinical laboratory. “We are looking forward to validating additional applications for DEPArray NxT technology including isolation of circulating tumor cells (CTCs) for liquid biopsy applications in a variety of solid tumors.”

“We are excited to see the launch our first DEPArray NxT-based clinical test in the U.S. Notably, this will provide physicians, and most importantly their patients, access to a solution in overcoming unresolved/equivocal HER2 status observed with tissue biopsies“ said Farideh Bischoff, PhD. Menarini Silicon Biosystems, Inc. Chief Clinical Development Officer.

The DEPArray HER2 test has a 5-7 day turn around time and can be performed in our CAP/CLIA certified laboratory on any archival tumor tissue sample. For more information about the test, please visit: http://www.pacificdx.com.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14765621.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. ResearchDx Appointment of New Chief Medical Officer to Meet NIH Push for Precision Medicine in Expediting Bench to Bedside" Strategies for Disease Treatment
2. ResearchDx and BioSmartSA Announce New Consulting Practice in Saudi Arabia
3. ResearchDx/PacificDx to Present High-Resolution HER2 Testing Data at the San Antonio Breast Cancer Symposium
4. Menarini and Meyer United In The Search For Rare Cells
5. Building quantum states with individual silicon atoms
6. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
7. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
8. MarketPublishers.com Added New Report on Silicon Tetrafluoride (CAS 7783-61-1) Market to Its Catalogue
9. NASA Scientists and Silicon Valley Space Center Partners Make Home Team Bid for Moffett Federal Airfield Development
10. MarketPublishers.com Added New Report on Silicon Nitride (CAS 12033-89-5) Market to Its Catalogue
11. Brainwave Signal Interpretation Software Company EyeMynd Announces Move to Silicon Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2019)... YORK and SOMERSET, N.J. (PRWEB) , ... June ... ... Catalent Biologics, today announced that they have entered into an agreement for production ... product candidates, IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) ...
(Date:6/12/2019)... EGG HARBOR TOWNSHIP, N.J. (PRWEB) , ... June ... ... premier manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, ... partnership agreement with Shanghai Zillion has been signed. The agreement will grant exclusive ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... in an upcoming episode, scheduled to broadcast 4Q/2019. Check your local listings for ... will educate viewers about how its technology facilitates laboratories to improve efficiency and ...
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, the ... national leader in opioid treatment, announced today they are partnering to combat the ... recently deployed its virtual care platform at the Mayo Clinic to drive shared ...
Breaking Biology Technology:
(Date:8/6/2019)... ... ... Keck Graduate Institute (KGI) President Sheldon Schuster has announced Martin Zdanowicz as the ... is highly regarded as an innovative leader who prioritizes student success and faculty development,” ... build on the success of the KGI School of Pharmacy and Health Sciences.” , ...
(Date:8/1/2019)... ... August 01, 2019 , ... The GENSPEED platform is a compact, fast and ... fully developed with over 100 units deployed in the field for multiple applications. ... collaboration with axiVEND will give us a foothold in the USA to better support ...
(Date:8/1/2019)... ... 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, Vice President ... addressing challenges with the upcoming EU MDR IVDR regulations . , ... variety of positions over his 26 years at the FDA, including developing the framework ...
Breaking Biology News(10 mins):